Entity
  • Adcendo

    Created in 2017
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    303 6,149
  • Activities

  • Technologies

  • Entity types

  • Location

    Nordre Fasanvej 215, 2000 Frederiksberg, Denmark

    Frederiksberg

    Denmark

  • Employees

    Scale: 11-50, 2-10

    Estimated: 52

  • Engaged corporates

    2
    0 2
  • Added in Motherbase

    1 year, 8 months ago
Description
  • Value proposition

    Development of highly differentiated first-in-class antibody-drug conjugates (ADCs) for treatment of solid tumors.

    Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors.

    In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic.

    Read more at www.adcendo.com

Corporate interactions BETA
Corporate TypeTweets Articles
NYSE
NYSE
Finance, Financial Services
NYSE
Finance, Financial Services
Other

30 Nov 2024


KKR
KKR
Startup accelerator & VC, Financial Services
KKR
Startup accelerator & VC, Financial Services
Other

29 May 2024


Similar entities
Loading...
Loading...
Social network dynamics